[go: up one dir, main page]

PE20120305A1 - Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl - Google Patents

Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl

Info

Publication number
PE20120305A1
PE20120305A1 PE2011001249A PE2011001249A PE20120305A1 PE 20120305 A1 PE20120305 A1 PE 20120305A1 PE 2011001249 A PE2011001249 A PE 2011001249A PE 2011001249 A PE2011001249 A PE 2011001249A PE 20120305 A1 PE20120305 A1 PE 20120305A1
Authority
PE
Peru
Prior art keywords
bcl
halogen
alkyl
inhbiders
tetrahydroquinoline
Prior art date
Application number
PE2011001249A
Other languages
English (en)
Inventor
Jonathon Bayldon Baell
Chihn Thien Bui
Peter Colman
Dannete A Dudley
Wayne J Fairbrother
John A Flygare
Guillaume Laurent Lassene
George Nikolakopoulos
Carl Steven Rye
Brad Edmund Sleebs
Brian John Smith
Keith Geoffrey Watson
Steven W Elmore
Andrew M Petros
Andrew J Souers
Chudi Ndubaku
Original Assignee
Abbott Lab
Genentech Inc
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120305(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab, Genentech Inc, Inst Medical W & E Hall filed Critical Abbott Lab
Publication of PE20120305A1 publication Critical patent/PE20120305A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE R1 ES ALQUILO C1-C6, ALQUENILO C2-C6, HALOGENO, ENTRE OTROS; n ES UN ENTERO DE 0 A 2; X1 ES CH2, O, S, SO, ENTRE OTROS; X2a, X2b Y X2c SON CH, CR2 O N; R2 ES CN, HALOGENO, NO2, ENTRE OTROS; A ES UN GRUPO (1), (2), (3), ENTRE OTROS; R3 ES CN, NO2, HALOGENO, ENTRE OTROS; B ES UN GRUPO (a) O (b); X3 ES NH, N(ALQUILO C1-C3), S; R4a ES ALQUILO C1-C4, ALQUINILO C2-C4, HALOGENO, ENTRE OTROS; R4b ES HALOGENO, NO2, CN, ENTRE OTROS; L ES ALQUILENO C1-C6, ALQUENILENO C2-C6, NH, S, ENTRE OTROS; E ES H, HALOGENO, FENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 6-(4-(BENZO[d]TIAZOL-2-ILCARBAMOIL)-1-METIL-1,2,3,4-TETRAHIDROQUINOXALIN-6-IL)PICOLINICO, ACIDO 6-(1-(BENZO[d]TIAZOL-2-ILCARBAMOIL)-1,2,3,4-TETRAHIDROQUINOLIN-7-IL)-3-(2-FENOXIETOXI)PICOLINICO, ACIDO 6-(1-(BENZO[d]TIAZOL-2-ILCARBAMOIL)-1,2,3,4-TETRAHIDROQUINOLIN-7-IL)-3-(2-(3-(DIMETILAMINO)FENOXI)ETOXI)PICOLINICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE LAS PROTEINAS Bcl-2 Y Bcl-Xl Y SON UTILES EN EL TRATAMIENTO DEL CANCER, TROMBOCITEMIA, ENTRE OTRAS
PE2011001249A 2008-12-19 2009-12-17 Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl PE20120305A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13947908P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
PE20120305A1 true PE20120305A1 (es) 2012-04-09

Family

ID=42316717

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001249A PE20120305A1 (es) 2008-12-19 2009-12-17 Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl

Country Status (21)

Country Link
US (3) US8114893B2 (es)
EP (1) EP2376085B1 (es)
JP (1) JP5683484B2 (es)
KR (1) KR101633532B1 (es)
CN (1) CN102325531B (es)
AU (1) AU2009335818A1 (es)
BR (1) BRPI0918337A2 (es)
CA (1) CA2747161C (es)
CO (1) CO6390110A2 (es)
CR (1) CR20110389A (es)
DO (1) DOP2011000198A (es)
EC (1) ECSP11011214A (es)
ES (1) ES2462715T3 (es)
IL (1) IL213547A0 (es)
MX (1) MX2011006514A (es)
NZ (1) NZ593536A (es)
PE (1) PE20120305A1 (es)
RU (1) RU2561109C2 (es)
SG (1) SG172266A1 (es)
WO (1) WO2010080478A1 (es)
ZA (1) ZA201104463B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101711235A (zh) 2007-04-16 2010-05-19 雅培制药有限公司 7-未取代的吲哚mcl-1抑制剂
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
ES2462715T3 (es) 2008-12-19 2014-05-26 Genentech, Inc. Compuestos y métodos de uso
PE20120334A1 (es) * 2008-12-19 2012-04-16 Abbott Lab COMPUESTOS HETEROCICLICOS INHIBIDORES DE LAS PROTEINAS ANTI-APOPTOTICAS Bcl2
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
EP2675275B1 (en) 2011-02-14 2017-12-20 The Regents Of The University Of Michigan Compositions and methods for the treatment of obesity and related disorders
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
TWI561521B (en) * 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013090645A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
ES2727898T3 (es) 2013-05-02 2019-10-21 Univ Michigan Regents Amlexanox deuterado con estabilidad metabólica mejorada
RU2550346C2 (ru) * 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
WO2015112801A1 (en) * 2014-01-24 2015-07-30 Purdue Pharma L.P. Pyridines and pyrimidines and use thereof
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
RU2716256C2 (ru) 2014-01-28 2020-03-11 Бак Инститьют Фо Ресеч Он Эйджинг Способы и композиции для уничтожения стареющих клеток и для лечения заболеваний и расстройств, ассоциированных со старением
CN103804367B (zh) * 2014-02-28 2016-09-14 天津药物研究院 苯并氮杂卓衍生物、其制备方法和用途
ES2763527T3 (es) 2014-04-04 2020-05-29 Univ Michigan Regents Inhibidores de molécula pequeña de mcl-1 y usos de los mismos
WO2015171591A1 (en) 2014-05-05 2015-11-12 Board Of Trustees Of The University Of Arkansas COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
CA2954268C (en) * 2014-07-08 2022-11-22 Dow Agrosciences Llc Process for the preparation of 3-hydroxypicolinic acids
AU2015292710A1 (en) 2014-07-22 2017-02-16 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
WO2016015815A1 (de) * 2014-07-28 2016-02-04 Merck Patent Gmbh Metallkomplexe
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CA2970161A1 (en) * 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds and antibody drug conjugates including the same
WO2016131100A1 (en) * 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2017132538A1 (en) 2016-01-29 2017-08-03 The Regents Of The University Of Michigan Amlexanox analogs
CA3018932C (en) 2016-03-28 2021-10-26 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
WO2017184995A1 (en) 2016-04-21 2017-10-26 Bioventures, Llc Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN108251377B (zh) * 2018-01-16 2021-08-27 内蒙古大学 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法
CA3088253A1 (en) 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
WO2019221755A1 (en) 2018-05-18 2019-11-21 Bioventures, Llc Piperlongumine analogues and uses thereof
EP3705109A1 (en) 2019-03-05 2020-09-09 Greenaltech, S.L. Carotenoids in the treatment of senescence-related diseases
CN117304171A (zh) * 2020-04-20 2023-12-29 深圳市塔吉瑞生物医药有限公司 吡嗪取代的烟酰胺的固体形式及其制备和用途
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
WO2022008464A1 (en) 2020-07-06 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
JP2023553811A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用方法
CA3206906A1 (en) 2021-02-02 2022-08-11 Andras Herner Selective bcl-xl protac compounds and methods of use
TW202345857A (zh) * 2022-03-08 2023-12-01 美商昂科斯克塞爾醫療有限責任公司 他波司他之穩定調配物
JP2025510762A (ja) * 2022-03-31 2025-04-15 ベイジーン スイッツァランド ゲーエムベーハー Ｂｃｌ－ｘＬ阻害剤
KR20250027281A (ko) 2022-05-20 2025-02-25 노파르티스 아게 Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
AU2023273734A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2332756A1 (fr) 1975-11-26 1977-06-24 Squibb & Sons Inc Nouvelles 1, 4-benzoxazin-3(4h)-ones
DE19929785A1 (de) 1999-06-29 2001-01-04 Bayer Ag Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung
WO2001057008A1 (en) * 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
JP4403305B2 (ja) * 2001-09-03 2010-01-27 武田薬品工業株式会社 １，３−ベンゾチアジノン誘導体および用途
CA2459224C (en) 2001-09-03 2012-05-08 Takeda Chemical Industries, Ltd. 1,3-benzothiazinone derivatives and the use thereof
PT1463563E (pt) 2001-12-14 2009-03-19 Alcon Inc Miméticos de dismutase do superóxido para o tratamento de distúrbios e doenças oculares
WO2007026920A2 (en) * 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US8022205B2 (en) 2006-08-08 2011-09-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivatives as PI3K inhibitor and use thereof
EP3243814B1 (en) 2007-04-16 2018-10-17 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
CN101711235A (zh) 2007-04-16 2010-05-19 雅培制药有限公司 7-未取代的吲哚mcl-1抑制剂
EP2193127A4 (en) 2007-09-27 2011-09-14 Inst Medical W & E Hall BENZOTHIAZOLE COMPOUNDS
JPWO2010027002A1 (ja) 2008-09-05 2012-02-02 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体
PE20120334A1 (es) 2008-12-19 2012-04-16 Abbott Lab COMPUESTOS HETEROCICLICOS INHIBIDORES DE LAS PROTEINAS ANTI-APOPTOTICAS Bcl2
ES2462715T3 (es) 2008-12-19 2014-05-26 Genentech, Inc. Compuestos y métodos de uso

Also Published As

Publication number Publication date
US8114893B2 (en) 2012-02-14
WO2010080478A1 (en) 2010-07-15
ECSP11011214A (es) 2011-09-30
JP2012512887A (ja) 2012-06-07
US8518970B2 (en) 2013-08-27
CO6390110A2 (es) 2012-02-29
ES2462715T3 (es) 2014-05-26
NZ593536A (en) 2013-07-26
US20100190782A1 (en) 2010-07-29
US20140005190A1 (en) 2014-01-02
EP2376085A4 (en) 2012-08-15
JP5683484B2 (ja) 2015-03-11
CA2747161A1 (en) 2010-07-15
CA2747161C (en) 2017-07-18
MX2011006514A (es) 2011-10-11
AU2009335818A1 (en) 2011-07-21
KR20110114581A (ko) 2011-10-19
CN102325531A (zh) 2012-01-18
HK1161094A1 (en) 2012-08-24
CN102325531B (zh) 2014-04-02
KR101633532B1 (ko) 2016-06-24
US20120184541A1 (en) 2012-07-19
RU2011129789A (ru) 2013-01-27
IL213547A0 (en) 2011-07-31
EP2376085A1 (en) 2011-10-19
SG172266A1 (en) 2011-07-28
CR20110389A (es) 2011-07-13
RU2561109C2 (ru) 2015-08-20
EP2376085B1 (en) 2014-02-26
US9067928B2 (en) 2015-06-30
DOP2011000198A (es) 2012-08-31
BRPI0918337A2 (pt) 2017-05-30
ZA201104463B (en) 2012-09-26

Similar Documents

Publication Publication Date Title
PE20120305A1 (es) Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20041016A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20141405A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20110308A1 (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa

Legal Events

Date Code Title Description
FC Refusal